Cavotec

Cavotec

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Cavotec - Low-margin legacy orders weigh on Q2

24 juli 2026

  • Q2: Sales of EUR 45m (36m), adj. EBIT of -EUR 1.1m (-0.7m)
  • P&M drives book-to-bill of 1.2x (R12m)
  • Upbeat outlook commentary

Growth delivers, mix weighs

Cavotec reported sales above expectations at EUR 45m, +25% y-o-y (20% vs ABGSCe). P&M: 34% y-o-y, Industry: 12% y-o-y. Similar to in Q1, there was a strong order intake of EUR 49m (11% y-o-y), which was broadly as we expected following the pre-announcement, but it had not been incorporated into our estimates (ABGSCe 36m), as it was announced after our preview was published. With the R12m book-to-bill standing at ~1.2x, we see a healthy demand outlook for P&M. Adj. EBIT was softer than expected at EUR -1.1m vs ABGSCe of EUR 3.5m, with management attributing the adverse mix effects to deliveries of low-margin P&M orders dating back to 2024. NRIs of EUR -1.1m (ABGSCe -2.0m) were incurred in the quarter, relating to restructuring costs under the ongoing cost-savings programme.

'26e adj. EBIT lowered on earnings miss

We raise sales by 5%/4%/4% for '26e/'27e/'28e due to the revenue beat in the quarter. The strong order momentum for its shore power solutions de-risks our sales growth in '27-'28e. However, '26e adj. EBIT is lowered ~EUR 4.6m on the miss in the quarter, while we lower by another EUR 3.8m for the remaining two quarters of the year. We expect a sequential return to earnings growth in Q3, as the delivery of motorised cables and hose reels will be delivered to a ship unloader. Importantly, the outlook commentary marks a step-change, with management noting that customers are placing orders again after a long period of hesitancy.

15-10x '27e-'28e EV/EBIT

While profitability continued to trail revenue growth in the quarter, we see potential in an increasing backlog with a higher margin profile. However, we believe that some patience is required, as we expect earnings growth to return in '27e. The share is currently trading at 15-10x EV/EBIT on '27e-'28e, vs the peer median of 14-13x.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys
2026-08-21 Generic - Investing while growing Generic Analys
2026-08-21 Impact Coatings - A quarter driven by Coating Ser... Impact Coat.. Analys
2026-08-21 Skolon - Sweden profitability gains continue Skolon Analys
2026-08-21 I-tech - Strongest quarter on record I-tech Analys
2026-08-20 Tempest Security - Patrols below plan Tempest Sec.. Analys
2026-08-20 Tempest Security - Progress made but expectations... Tempest Sec.. Analys
2026-08-20 Ascelia Pharma - Still alive: Fighting to reverse... Ascelia Pharma Analys
2026-08-20 Clavister - Defence drives record quarter Clavister Analys
2026-08-20 Catella - Q2 softer than expected, but underlying... Catella Analys
2026-08-20 Generic - Volumes continue to grow Generic Analys
2026-08-19 SinterCast - Past the trough, but recovery pace u... SinterCast Analys
2026-08-19 Xplora Technologies - EBITDA -13% on soft senior ... Xplora Tech.. Analys